Contact
searchSearch
HMP Global

Biosimilars

Featured Article

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
Addressing and Understanding Challenges Linked With Adopting Biosimilars Into Practice
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
Identifying Pharmacist Knowledge of a Medication Drug Type
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
Most Pharmacists Show Good Grasp of Biosimilar Medications, Study Finds
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
Biosimilar Infliximab Appears Effective in Crohn`s Disease
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
Etanercept Biosimilar is Effective, Well-Tolerated for Rheumatoid Arthritis
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network

Newsfeed

News
ValuHealth Extra Strength Acetaminophen Recalled Due to Incorrect Labeling
11/05/2026
Rebecca Amrick
ValuHealth extra strength acetaminophen is under a voluntary Class III recall after the product was incorrectly labeled, affecting 100 134 bottles.
ValuHealth extra strength acetaminophen is under a voluntary Class III recall after the product was incorrectly labeled, affecting 100 134 bottles.
ValuHealth extra strength...
11/05/2026
Pharmacy Learning Network
News
Formoterol Fumarate Inhalation Solution Recalled Due to Failed Impurities Specifications
11/05/2026
Rebecca Amrick
A voluntary Class II recall has been issued for formoterol fumarate inhalation solution due to the product’s failure to meet impurities specifications, a discrepancy that affects 3210 cartons.
A voluntary Class II recall has been issued for formoterol fumarate inhalation solution due to the product’s failure to meet impurities specifications, a discrepancy that affects 3210 cartons.
A voluntary Class II recall has...
11/05/2026
Pharmacy Learning Network
News
Metoclopramide Tablets Recalled Due to Cross Contamination
11/05/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for metoclopramide tablets due to cross contamination with other tablets.
The US Food and Drug Administration (FDA) has issued a Class II recall for metoclopramide tablets due to cross contamination with other tablets.
The US Food and Drug...
11/05/2026
Pharmacy Learning Network
PharmLaw
Department of Labor Finalizes PBM Transparency Rule Expanding Compensation Disclosure Requirements
11/04/2026
Hannah Musick
The US Department of Labor has finalized new transparency requirements for pharmacy benefit managers, mandating expanded compensation disclosures and audit provisions to strengthen employer health plan oversight and accountability under the...
The US Department of Labor has finalized new transparency requirements for pharmacy benefit managers, mandating expanded compensation disclosures and audit provisions to strengthen employer health plan oversight and accountability under the...
The US Department of Labor has...
11/04/2026
Pharmacy Learning Network
News
Cinacalcet Tablets Recalled Due to Failed Dissolution Specifications
10/29/2026
Rebecca Amrick
Cinacalcet tablets are under a voluntary Class II recall due to the product’s failure to meet dissolution specifications, affecting 49 488 bottles.
Cinacalcet tablets are under a voluntary Class II recall due to the product’s failure to meet dissolution specifications, affecting 49 488 bottles.
Cinacalcet tablets are under a...
10/29/2026
Pharmacy Learning Network
News
Heparin Sodium Injection Recalled Due to Lack of Sterility Assurance
10/29/2026
Rebecca Amrick
A voluntary Class II recall has been issued for heparin sodium injection due to the product’s lack of sterility assurance, affecting 251 000 vials.
A voluntary Class II recall has been issued for heparin sodium injection due to the product’s lack of sterility assurance, affecting 251 000 vials.
A voluntary Class II recall has...
10/29/2026
Pharmacy Learning Network
News
Abirtega Recalled Over Tablet Weight Uniformity
10/29/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Abirtega (abiraterone acetate) after the tablets failed to meet weight uniformity specifications, affecting 2136 bottles.
The US Food and Drug Administration (FDA) has issued a Class II recall for Abirtega (abiraterone acetate) after the tablets failed to meet weight uniformity specifications, affecting 2136 bottles.
The US Food and Drug...
10/29/2026
Pharmacy Learning Network
PharmLaw
Fraudulent Prescriptions Lead to Conviction in $8.6 Million Medicare Scheme
10/28/2026
Grace Taylor, MS, MA
A Florida durable medical equipment company owner was convicted for her role in an $8.6 million Medicare fraud scheme involving falsified prescriptions, illegal kickbacks, and claims for medically unnecessary orthotic braces.
A Florida durable medical equipment company owner was convicted for her role in an $8.6 million Medicare fraud scheme involving falsified prescriptions, illegal kickbacks, and claims for medically unnecessary orthotic braces.
A Florida durable medical...
10/28/2026
Pharmacy Learning Network
News
Sermorelin Recalled Due to Lack of Process Control
10/22/2026
Rebecca Amrick
Sermorelin is under a voluntary Class II recall due to a lack of process control, affecting 7 vials.
Sermorelin is under a voluntary Class II recall due to a lack of process control, affecting 7 vials.
Sermorelin is under a voluntary...
10/22/2026
Pharmacy Learning Network
News
Tirzepatide/Niacinamide Recalled Due to Lack of Sterility Assurance
10/22/2026
Rebecca Amrick
A voluntary Class II recall has been issued for tirzepatide/niacinamide due to the product’s lack of sterility assurance, affecting 64 vials.
A voluntary Class II recall has been issued for tirzepatide/niacinamide due to the product’s lack of sterility assurance, affecting 64 vials.
A voluntary Class II recall has...
10/22/2026
Pharmacy Learning Network

Insights

Interactive Features

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use